A Practical Approach for Primary Care Practitioners to Evaluate and Manage Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia.
Journal
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
ISSN: 1078-4497
Titre abrégé: Fed Pract
Pays: United States
ID NLM: 9500574
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
18
2
2022
pubmed:
19
2
2022
medline:
19
2
2022
Statut:
ppublish
Résumé
Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) are common clinical encounters for most primary care practitioners (PCPs). More than 50% of men aged > 50 years will develop significant lower urinary tract symptoms. Managing these symptoms can be complicated and requires an informed discussion between the PCP and the patient. This article provides a comprehensive review for PCPs regarding the evaluation and management of LUTS in men and when to consider a urology referral. Over the past 3 decades, medications have become the most common BPH and LUTS therapy, but recently, newer minimally invasive surgeries have challenged this paradigm. PCPs are in a unique position to help many patients who present with early stage LUTS. A clear understanding of the available treatment options will help PCPs counsel patients appropriately about lifestyle modification, medications, and surgical treatment options for their symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) are common clinical encounters for most primary care practitioners (PCPs). More than 50% of men aged > 50 years will develop significant lower urinary tract symptoms. Managing these symptoms can be complicated and requires an informed discussion between the PCP and the patient. This article provides a comprehensive review for PCPs regarding the evaluation and management of LUTS in men and when to consider a urology referral.
OBSERVATIONS
METHODS
Over the past 3 decades, medications have become the most common BPH and LUTS therapy, but recently, newer minimally invasive surgeries have challenged this paradigm. PCPs are in a unique position to help many patients who present with early stage LUTS.
CONCLUSIONS
CONCLUSIONS
A clear understanding of the available treatment options will help PCPs counsel patients appropriately about lifestyle modification, medications, and surgical treatment options for their symptoms.
Identifiants
pubmed: 35177887
doi: 10.12788/fp.0197
pii: fp-38-12-573
pmc: PMC8843009
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
573-581Informations de copyright
Copyright © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA.
Déclaration de conflit d'intérêts
Author disclosures The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.
Références
Rev Urol. 2005;7 Suppl 9:S3-S14
pubmed: 16985902
Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):340-348
pubmed: 29316005
Eur Urol. 2015 Sep;68(3):418-25
pubmed: 25465970
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8
pubmed: 16613526
Curr Opin Urol. 2014 Nov;24(6):553-9
pubmed: 25232762
Sex Med Rev. 2013 May;1(1):24-41
pubmed: 27784557
BJU Int. 2017 May;119(5):767-775
pubmed: 27862831
Urology. 2019 Apr;126:171-179
pubmed: 30677455
N Engl J Med. 2003 Dec 18;349(25):2387-98
pubmed: 14681504
Cochrane Database Syst Rev. 2018 Nov 16;11:CD010060
pubmed: 30480763
PLoS One. 2017 Apr 4;12(4):e0174586
pubmed: 28376120
Can J Urol. 2017 Jun;24(3):8802-8813
pubmed: 28646935
J Urol. 2013 Apr;189(4):1388-95
pubmed: 23079373
Pharmacopsychiatry. 2016 Jan;49(1):3-13
pubmed: 26569417
J Urol. 2013 Dec;190(6):2161-7
pubmed: 23764081
JAMA Intern Med. 2019 Aug 1;179(8):1084-1093
pubmed: 31233095
Res Rep Urol. 2017 Aug 21;9:159-168
pubmed: 28861405
Curr Urol Rep. 2020 Oct 30;21(12):58
pubmed: 33128142
Urology. 1998 Aug;52(2):195-201; discussion 201-2
pubmed: 9697781
Eur Urol. 1999;36(1):1-13
pubmed: 10364649
Andrology. 2017 Jul;5(4):671-678
pubmed: 28453908
Urol Pract. 2017 May;4(3):193-199
pubmed: 28580382
J Endourol. 2020 Jul;34(7):778-781
pubmed: 32408768
Nat Clin Pract Urol. 2008 Oct;5(10):540-9
pubmed: 18836463
J Urol. 2020 Oct;204(4):799-804
pubmed: 32698710
Eur Urol. 2015 Oct;68(4):643-52
pubmed: 25937539
Ther Clin Risk Manag. 2009 Jun;5(3):535-45
pubmed: 19707263
Can J Urol. 2019 Aug;26(4 Suppl 1):2-7
pubmed: 31481142
JAMA. 2006 Nov 15;296(19):2319-28
pubmed: 17105794
N Engl J Med. 1998 Feb 26;338(9):557-63
pubmed: 9475762
Neurourol Urodyn. 2017 Feb;36(2):221-244
pubmed: 27918122
J Urol. 2013 Jan;189(1 Suppl):S102-6
pubmed: 23234610
Urol Clin North Am. 2013 Nov;40(4):613-35
pubmed: 24182980
J Urol. 2018 Sep;200(3):612-619
pubmed: 29775639
Neurourol Urodyn. 2014 Jan;33(1):17-30
pubmed: 24127366
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402
pubmed: 18471794
JAMA Intern Med. 2017 May 1;177(5):683-691
pubmed: 28319231
BJU Int. 2011 Mar;107(6):946-54
pubmed: 21332630
Eur Urol. 2006 Nov;50(5):969-79; discussion 980
pubmed: 16469429
Saudi J Anaesth. 2016 Jul-Sep;10(3):317-21
pubmed: 27375388
BJU Int. 2020 Jan;125(1):112-122
pubmed: 31599044
Nat Rev Urol. 2011 Jan;8(1):29-41
pubmed: 21228820
Med Devices (Auckl). 2016 May 19;9:115-23
pubmed: 27274321
Am Fam Physician. 2017 Jan 1;95(1):29-34
pubmed: 28075109
World J Urol. 2021 Jul;39(7):2301-2306
pubmed: 33569641